Camellia S. Huang

Camellia S. Huang

Auto-generated profile, based on publicly available information

Camellia S. Huang

Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in Science Advances
Verified
Journal Article
Open access
HMHarihar M. Mohan
Harihar M. Mohan
MFMartin G. Fernandez
Martin G. Fernandez
CHCamellia Huang
Camellia Huang
RLRita Lin
Rita Lin
JRJaimie H. Ryou
Jaimie H. Ryou
LSLisa M. Sharkey
Lisa M. Sharkey
The human genome is replete with sequences derived from foreign elements including endogenous retrovirus-like proteins of unknown function. Here, we show that UBQLN2, a ubiquitin-proteasome shuttle factor implicated in neurodegenerative diseases, is regulated by the linked actions of two retrovirus-like proteins, retrotransposon gag-like 8 (RTL8) and paternally expressed gene 10 (PEG10). RTL8 confers on UBQLN2 the ability to complex with and regulate PEG10. PEG10, a core component of stress granules, drives the recruitment of UBQLN2 to stress granules under various stress conditions but can only do so when RTL8 is present. Changes in UBQLN2, RTL8, or PEG10 levels further remodel the kinetics of stress granule disassembly and translation recovery. PEG10 also alters overall stress granule composition by incorporating select extracellular vesicle proteins. Within stress granules, PEG10 forms virus-like particles, underscoring the structural heterogeneity of this class of biomolecular condensates. Together, these results reveal an unexpected link between pathways of cellular proteostasis and endogenous retrovirus-like proteins.

20 October 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
FWFang Wang
Fang Wang
JBJonathan Braverman
Jonathan Braverman
GEGeorge Eng
George Eng
OLOzen Leylek
Ozen Leylek
NPNicholas L. Petrone
Nicholas L. Petrone
ÖYÖmer H. Yilmaz
Ömer H. Yilmaz
A common mechanism by which cancer cells acquire resistance to chemotherapeutics is through the overexpression of efflux pumps, enabling the removal of cytotoxic agents, such as anthracycline drugs. However, platinum anticancer agents that crosslink DNA and interact with proteins are poor efflux pump substrates. Here, we design dual warhead drug conjugates by tethering a platinum pharmacophore to the doxorubicin backbone. These drug conjugates retain the anticancer activity of anthracyclines and exhibit the ability to both circumvent drug efflux and delay the acquisition of drug resistance. In vivo experiments demonstrate that such drug conjugates extend survival in a preclinical organoid-based model of metastatic colon cancer in mice. Mechanistic studies indicate that these drug conjugates overcome resistance through covalent platinum-protein interactions, leading to significantly improved drug retention and alteration of subcellular drug distribution. This application of platinum offers many opportunities to confront issues related to chemoresistance and alternative pathways for augmenting conventional chemotherapeutics.